eISSN 2287-9803 
pISSN 2287-9412 
Aims and Scope
Ethical Guidelines
Editoral Board
Forthcomming Issue
Current Issue
Most Read Articles
Informaion for Authors
Check List
Contact us
Brief communication
  |     |   J Korean Soc Neonatol._18_2_409_411.pdf
J Korean Soc Neonatol. November;18(2):409-411.
Published online 2011 November 25   doi: https://doi.org/10.5385/jksn.2011.18.2.409
Copyright ⓒ 2011 The Korean Society of Neonatology Neonatal Medicine
Surfactant Replacement Therapy for RDS: a Collaborative Study of 72 Multi-center Trials in Korea (2010) and a Review of Korean Experiences over 20 Years
Chong-Woo Bae, M.D., Won Ho Hahn, M.D., Ji Young Chang, M.D. and Sung Mi Kim, M.D*
Department of Pediatrics, Kyung Hee University School of Medicine, Seoul, Korea
Department of Pediatrics*, Busan St. Mary's Medical Center, Busan, Korea
Corresponding Author: Chong-Woo Bae, M.D. , Tel: +82-2-440-6130 , Fax: +82-2-440-7175 , Email: baecw@khnmc.or.kr
In Korea, pulmonary surfactant (PS) replacement therapy in respiratory distress syndrome (RDS) was started in 1991 since when Surfacten® was imported from Japan. At the present time, Surfacten®, Newfactan®, Curosurf®, and Infasurf® are available in Korea. The governmental health insurance covers the expense for multiple dose treatment since 2002 and the early prophylactic treatment (BW: <1,250 g or GP: <30 wks) since 2011. We undertook a multi-institutional collective study to evaluate the outcomes of PS over past 20 years in Korea (Period-I; 1990/91, P-II; 1996, P-III; 2002, and P-IV; 2007, P-V; 2010). There were 60 RDS neonates with PS treatment in P-I (16 hospitals), 1,179 in P-II (64), 1,595 in P-III (62), 1,921 in P-IV (57), and 3,160 in P-V (72). Decreased mortality rate, defined as the percentage of neonates who died within 28 days of birth, was seen between periods, P-V vs P-I, II, III, and IV (mortality rate: 10.1% vs. 40.0%, 30.0%, 18.7%, and 14.3%). We conclude that PS therapy contributed to improve remarkable outcome in RDS neonates over the last 20 years in Korea. However, more efforts should be made to optimize PS therapy for better outcome. Multiple PS doses for relapse and poor response, early prophylactic use, and better supportive care for pre-term infants are mandatory.
Keywords: Respiratory distress syndrome, Newborn, Premature, Complications, Epidemiology mortality pulmonary surfactant, Analysis therapeutic use data collection
Copyright(c) By Korean Society of Neonatology. All right reserved.
Rm.1207, King's garden 3 Block, 34, Sajik-ro 8-gil, Jongno-gu, Seoul 110-872, Korea. TEL: +82-2-730-1993 FAX: +82-2-730-1994 Email:neonate2002@hanmail.net